Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity

被引:5
|
作者
Flury, Philipp [1 ,2 ]
Breidenbach, Julian [3 ]
Krueger, Nadine [4 ]
Voget, Rabea [3 ]
Schaekel, Laura [3 ]
Si, Yaoyao [3 ]
Krasniqi, Vesa [3 ]
Calistri, Sara [1 ,2 ]
Olfert, Matthias [5 ]
Sylvester, Katharina [3 ]
Rocha, Cheila [4 ]
Ditzinger, Raphael [1 ,2 ]
Rasch, Alexander [1 ,2 ]
Poehlmann, Stefan [4 ,5 ]
Kronenberger, Thales [1 ,2 ,6 ,7 ]
Poso, Antti [1 ,2 ,6 ]
Rox, Katharina [8 ,9 ]
Laufer, Stefan A. [1 ,2 ]
Mueller, Christa E. [2 ,3 ]
Guetschow, Michael [3 ]
Pillaiyar, Thanigaimalai [1 ,2 ]
机构
[1] Eberhard Karls Univ Tubingen, Inst Pharm Pharmaceut Med Chem, D-72076 Tubingen, Germany
[2] Eberhard Karls Univ Tubingen, Tubingen Ctr Acad Drug Discovery, D-72076 Tubingen, Germany
[3] Univ Bonn, Pharmaceut Inst, PharmaCtr Bonn, Pharmaceut & Med Chem, D-53121 Bonn, Germany
[4] Leibniz Inst Primate Res, German Primate Ctr, Infect Biol Unit, D-37077 Gottingen, Germany
[5] Univ Goettingen, Fac Biol & Psychol, D-37073 Gottingen, Germany
[6] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70211, Finland
[7] Excellence Cluster Controlling Microbes Fight Inf, D-72076 Tubingen, Germany
[8] Helmholtz Ctr Infect Res HZI, Dept Chem Biol, D-38124 Braunschweig, Germany
[9] German Ctr Infect Res DZIF, Partner Site Hannover Braunschweig, D-38124 Braunschweig, Germany
关键词
COVID-19; cathepsininhibitors; main protease; peptidomimetics; SARS-CoV-2; viral entry; MAIN PROTEASE; CYSTEINE; ENTRY; REACTIVITY; DISCOVERY;
D O I
10.1021/acsptsci.3c00313
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cathepsins (Cats) are proteases that mediate the successful entry of SARS-CoV-2 into host cells. We designed and synthesized a tailored series of 21 peptidomimetics and evaluated their inhibitory activity against human cathepsins L, B, and S. Structural diversity was realized by combinations of different C-terminal warhead functions and N-terminal capping groups, while a central Leu-Phe fragment was maintained. Several compounds were identified as promising cathepsin L and S inhibitors with K-i values in the low nanomolar to subnanomolar range, for example, the peptide aldehydes 9a and 9b (9a, 2.67 nM, CatL; 0.455 nM, CatS; 9b, 1.76 nM, CatL; 0.512 nM, CatS). The compounds' inhibitory activity against the main protease of SARS-CoV-2 (M-pro) was additionally investigated. Based on the results at CatL, CatS, and M-pro, selected inhibitors were subjected to investigations of their antiviral activity in cell-based assays. In particular, the peptide nitrile 11e exhibited promising antiviral activity with an EC50 value of 38.4 nM in Calu-3 cells without showing cytotoxicity. High metabolic stability and favorable pharmacokinetic properties make 11e suitable for further preclinical development.
引用
收藏
页码:493 / 514
页数:22
相关论文
共 50 条
  • [21] Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
    Katagishi, Daiki
    Yasuda, Daisuke
    Takahashi, Kyoko
    Nakamura, Shigeo
    Mashino, Tadahiko
    Ohe, Tomoyuki
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 80
  • [22] Potential protease inhibitors and their combinations to block SARS-CoV-2
    Abhinand, Chandran S.
    Nair, Achuthsankar S.
    Krishnamurthy, Anand
    Oommen, Oommen V.
    Sudhakaran, Perumana R.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (02) : 903 - 917
  • [23] Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors
    Diogo, Marcel Arruda
    Cabral, Augusto Gomes Teixeira
    de Oliveira, Renata Barbosa
    PATHOGENS, 2024, 13 (10):
  • [24] Design, synthesis, and antiviral activity of fragmented-lapatinib aminoquinazoline analogs towards SARS-CoV-2 inhibition
    Adediji, Ayomide
    Sroithongmoon, Akeanan
    Suroengrit, Aphinya
    Wilasluck, Patcharin
    Deetanya, Peerapon
    Sanachai, Kamonpan
    Karnchanapandh, Kun
    Boonyasuppayakorn, Siwaporn
    Wangkanont, Kittikhun
    Rungrotmongkol, Thanyada
    Khotavivattana, Tanatorn
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 286
  • [25] Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors
    Bao, Hong-Lei
    Tu, Gao
    Yue, Qiu
    Liu, Pei
    Zheng, Hui-Li
    Yao, Xiao-Jun
    CHEMICAL BIOLOGY & DRUG DESIGN, 2023, 102 (04) : 857 - 869
  • [26] Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 Mpro Inhibitors
    Jacobs, Leon
    van der Westhuyzen, Aletta
    Pribut, Nicole
    Dentmon, Zackery W.
    Cui, Dan
    D'Erasmo, Michael P.
    Bartsch, Perry W.
    Liu, Ken
    Cox, Robert M.
    Greenlund, Sujay F.
    Plemper, Richard K.
    Mitchell, Deborah
    Marlow, Joshua
    Andrews, Meghan K.
    Krueger, Rebecca E.
    Sticher, Zachary M.
    Kolykhalov, Alexander A.
    Natchus, Michael G.
    Zhou, Bin
    Pelly, Stephen C.
    Liotta, Dennis C.
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, : 1434 - 1440
  • [27] Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents
    Ayaz, Sameer
    Crea, Francesco
    EPIGENOMICS, 2020, 12 (10) : 811 - 812
  • [28] Design, Synthesis, and Biological Evaluation of 5,8-Dimethyl Shikonin Oximes as SARS-CoV-2 Mpro Inhibitors
    Cui, Jiahua
    Xiang, Shouyan
    Zhang, Qijing
    Xiao, Shangqing
    Yuan, Gaoyang
    Liu, Chenwu
    Li, Shaoshun
    MOLECULES, 2025, 30 (06):
  • [29] Neutron crystallography for drug design targeting SARS-CoV-2 viral proteins
    Kovalevsky, A.
    Kneller, D.
    Coates, L.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2021, 77 : C613 - C613
  • [30] Design, synthesis and evaluation of inhibitors of the SARS-CoV-2 nsp3 macrodomain
    Sherrill, Lavinia M.
    Joya, Elva E.
    Walker, AnnMarie
    Roy, Anuradha
    Alhammad, Yousef M.
    Atobatele, Moriama
    Wazir, Sarah
    Abbas, George
    Keane, Patrick
    Zhuo, Junlin
    Leung, Anthony K. L.
    Johnson, David K.
    Lehtio, Lari
    Fehr, Anthony R.
    Ferraris, Dana
    BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 67